The investment includes other related expenditure and will be funded through internal accruals. The company said the land is proposed to be used for its future expansion. There is no proposed capacity addition specified as part of the current announcement.
Neuland Laboratories also has a right of first refusal to purchase an additional contiguous land parcel of approximately 66 acres at a later date. If acquired, the potential aggregate land parcel at the location would increase to approximately 200 acres.
ALSO READ | Neuland Labs Q4 Result: Profit surges 7x to ₹213 crore as export orders drive strong quarter
First Quarter Results
The company reported a net profit of ₹148 crore for the quarter ended June 30, 2026, compared with ₹14 crore in the corresponding period last year. Revenue from operations more than doubled during the quarter, rising to ₹641.5 crore from ₹292.7 crore a year earlier.
Earnings before interest, tax, depreciation and amortisation (EBITDA) surged to ₹222.7 crore from ₹34.4 crore in the year-ago quarter. As a result, EBITDA margin expanded sharply to 34.7% from 11.8% in the corresponding quarter last year.
The company also reported higher total income, which increased to ₹650.1 crore from ₹300.6 crore in the corresponding quarter last year. Profit before tax rose to ₹197.5 crore from ₹17.4 crore, while profit after tax stood at ₹147.4 crore compared with ₹13.7 crore in the year-ago period.
ALSO READ | Neuland Laboratories Q2 Results | Net profit jumps over 2-fold on strong CMS project revenue
Shares of Neuland Laboratories Ltd ended at ₹22,955.00, up by ₹311.70, or 1.38%, on the BSE.
First Published: Sept 7, 2026 6:44 PM IST
